Loading…

The La Autoantigen Is a Malignancy-Associated Cell Death Target That Is Induced by DNA-Damaging Drugs

Purpose: To evaluate the La autoantigen as a target for specific monoclonal antibody (mAb) binding in dead cancer cells after use of DNA-damaging chemotherapy. Experimental Design: In vitro studies of La-specific 3B9 mAb binding to malignant and normal primary cells with and without cytotoxic drug t...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2007-09, Vol.13 (18), p.5509s-5518s
Main Authors: Al-Ejeh, Fares, Darby, Jocelyn M, Brown, Michael P
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c403t-c4185777c0ed33a5a6be294482f5e71fb37ccfcd4c5a288dc9d3707606e6b5683
cites cdi_FETCH-LOGICAL-c403t-c4185777c0ed33a5a6be294482f5e71fb37ccfcd4c5a288dc9d3707606e6b5683
container_end_page 5518s
container_issue 18
container_start_page 5509s
container_title Clinical cancer research
container_volume 13
creator Al-Ejeh, Fares
Darby, Jocelyn M
Brown, Michael P
description Purpose: To evaluate the La autoantigen as a target for specific monoclonal antibody (mAb) binding in dead cancer cells after use of DNA-damaging chemotherapy. Experimental Design: In vitro studies of La-specific 3B9 mAb binding to malignant and normal primary cells with and without cytotoxic drug treatment were done using immunoblotting and flow cytometry. Chromatin-binding studies and immunofluorescence detection of γH2AX as a marker of DNA double-stranded breaks together with 3B9 binding assays were done to measure DNA damage responses. Incorporation of a transglutaminase 2 (TG2) substrate and TG2 inhibition were studied to measure protein cross-linking in dead cells. Results: La was overexpressed in human cancer cell lines with respect to normal primary cells. Within 3 h of the DNA-damaging stimulus, La became chromatin bound when it colocalized with γH2AX. Later, after the stimulus produced cell death, La-specific 3B9 mAb bound specifically and preferentially in the cytoplasm of dead cancer cells. Moreover, 3B9 binding to dead cancer cells increased with increasing DNA damage. Both La and 3B9 became cross-linked in dead cancer cells via TG2 activity. Conclusion: La autoantigen represents a promising cancer cell death target to determine chemotherapy response because its expression was selectively induced in dead cancer cells after DNA-damaging chemotherapy.
doi_str_mv 10.1158/1078-0432.CCR-07-0922
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19735442</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19735442</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-c4185777c0ed33a5a6be294482f5e71fb37ccfcd4c5a288dc9d3707606e6b5683</originalsourceid><addsrcrecordid>eNpF0E1v0zAYwHELMbEx-AggX9gBKcMvcewcq3RApQ4kVM7WE-dJYpQmw0409dvjqEW72D78Htv6E_KBs3vOlfnCmTYZy6W4r6pfGdMZK4V4RW64UjqTolCv0_m_uSZvY_zDGM85y9-Qa66NVtrIG4KHHuke6GaZJxhn3-FId5ECfYTBdyOM7pRtYpychxkbWuEw0C3C3NMDhA5neuhhXid2Y7O4JOoT3f7YZFs4QufHjm7D0sV35KqFIeL7y35Lfn99OFTfs_3Pb7tqs89czuScVm6U1toxbKQEBUWNosxzI1qFmre11M61rsmdAmFM48pGaqYLVmBRq8LIW3J3vvcpTH8XjLM9-ujSn2HEaYmWl1qqPBcJqjN0YYoxYGufgj9COFnO7NrXru3s2s6mvpZpu_ZNcx8vDyz1EZuXqUvQBD5dAEQHQxtSQR9fXCk4LwqV3Oez633XP_uA1iWJIWBECK63XFpurFKsjPIfEZmQSQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19735442</pqid></control><display><type>article</type><title>The La Autoantigen Is a Malignancy-Associated Cell Death Target That Is Induced by DNA-Damaging Drugs</title><source>Freely Accessible Science Journals - check A-Z of ejournals</source><creator>Al-Ejeh, Fares ; Darby, Jocelyn M ; Brown, Michael P</creator><creatorcontrib>Al-Ejeh, Fares ; Darby, Jocelyn M ; Brown, Michael P</creatorcontrib><description>Purpose: To evaluate the La autoantigen as a target for specific monoclonal antibody (mAb) binding in dead cancer cells after use of DNA-damaging chemotherapy. Experimental Design: In vitro studies of La-specific 3B9 mAb binding to malignant and normal primary cells with and without cytotoxic drug treatment were done using immunoblotting and flow cytometry. Chromatin-binding studies and immunofluorescence detection of γH2AX as a marker of DNA double-stranded breaks together with 3B9 binding assays were done to measure DNA damage responses. Incorporation of a transglutaminase 2 (TG2) substrate and TG2 inhibition were studied to measure protein cross-linking in dead cells. Results: La was overexpressed in human cancer cell lines with respect to normal primary cells. Within 3 h of the DNA-damaging stimulus, La became chromatin bound when it colocalized with γH2AX. Later, after the stimulus produced cell death, La-specific 3B9 mAb bound specifically and preferentially in the cytoplasm of dead cancer cells. Moreover, 3B9 binding to dead cancer cells increased with increasing DNA damage. Both La and 3B9 became cross-linked in dead cancer cells via TG2 activity. Conclusion: La autoantigen represents a promising cancer cell death target to determine chemotherapy response because its expression was selectively induced in dead cancer cells after DNA-damaging chemotherapy.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-07-0922</identifier><identifier>PMID: 17875783</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antibodies, Monoclonal - pharmacology ; Antineoplastic agents ; Antineoplastic Agents - toxicity ; Apoptosis - drug effects ; Apoptosis - physiology ; Autoantigens - immunology ; Autoantigens - metabolism ; Biological and medical sciences ; cell death ; Chromatin - metabolism ; Cisplatin - toxicity ; Cross-Linking Reagents - pharmacology ; DNA Breaks, Double-Stranded - drug effects ; DNA damage ; DNA, Neoplasm - drug effects ; Flow Cytometry ; Fluorescent Antibody Technique ; GTP-Binding Proteins - metabolism ; Histones - metabolism ; Humans ; Immunoblotting ; La/SSB ; Lymphocytes - drug effects ; Medical sciences ; Monocytes - drug effects ; Necrosis ; Neoplasms - genetics ; Neoplasms - metabolism ; Neoplasms - pathology ; Pharmacology. Drug treatments ; Protein Glutamine gamma Glutamyltransferase 2 ; ribonucleoprotein ; Ribonucleoproteins - antagonists &amp; inhibitors ; Ribonucleoproteins - immunology ; Ribonucleoproteins - metabolism ; SS-B Antigen ; transglutaminase ; Transglutaminases - metabolism ; Tumor Cells, Cultured</subject><ispartof>Clinical cancer research, 2007-09, Vol.13 (18), p.5509s-5518s</ispartof><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-c4185777c0ed33a5a6be294482f5e71fb37ccfcd4c5a288dc9d3707606e6b5683</citedby><cites>FETCH-LOGICAL-c403t-c4185777c0ed33a5a6be294482f5e71fb37ccfcd4c5a288dc9d3707606e6b5683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=19211665$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17875783$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Ejeh, Fares</creatorcontrib><creatorcontrib>Darby, Jocelyn M</creatorcontrib><creatorcontrib>Brown, Michael P</creatorcontrib><title>The La Autoantigen Is a Malignancy-Associated Cell Death Target That Is Induced by DNA-Damaging Drugs</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Purpose: To evaluate the La autoantigen as a target for specific monoclonal antibody (mAb) binding in dead cancer cells after use of DNA-damaging chemotherapy. Experimental Design: In vitro studies of La-specific 3B9 mAb binding to malignant and normal primary cells with and without cytotoxic drug treatment were done using immunoblotting and flow cytometry. Chromatin-binding studies and immunofluorescence detection of γH2AX as a marker of DNA double-stranded breaks together with 3B9 binding assays were done to measure DNA damage responses. Incorporation of a transglutaminase 2 (TG2) substrate and TG2 inhibition were studied to measure protein cross-linking in dead cells. Results: La was overexpressed in human cancer cell lines with respect to normal primary cells. Within 3 h of the DNA-damaging stimulus, La became chromatin bound when it colocalized with γH2AX. Later, after the stimulus produced cell death, La-specific 3B9 mAb bound specifically and preferentially in the cytoplasm of dead cancer cells. Moreover, 3B9 binding to dead cancer cells increased with increasing DNA damage. Both La and 3B9 became cross-linked in dead cancer cells via TG2 activity. Conclusion: La autoantigen represents a promising cancer cell death target to determine chemotherapy response because its expression was selectively induced in dead cancer cells after DNA-damaging chemotherapy.</description><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - toxicity</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis - physiology</subject><subject>Autoantigens - immunology</subject><subject>Autoantigens - metabolism</subject><subject>Biological and medical sciences</subject><subject>cell death</subject><subject>Chromatin - metabolism</subject><subject>Cisplatin - toxicity</subject><subject>Cross-Linking Reagents - pharmacology</subject><subject>DNA Breaks, Double-Stranded - drug effects</subject><subject>DNA damage</subject><subject>DNA, Neoplasm - drug effects</subject><subject>Flow Cytometry</subject><subject>Fluorescent Antibody Technique</subject><subject>GTP-Binding Proteins - metabolism</subject><subject>Histones - metabolism</subject><subject>Humans</subject><subject>Immunoblotting</subject><subject>La/SSB</subject><subject>Lymphocytes - drug effects</subject><subject>Medical sciences</subject><subject>Monocytes - drug effects</subject><subject>Necrosis</subject><subject>Neoplasms - genetics</subject><subject>Neoplasms - metabolism</subject><subject>Neoplasms - pathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Glutamine gamma Glutamyltransferase 2</subject><subject>ribonucleoprotein</subject><subject>Ribonucleoproteins - antagonists &amp; inhibitors</subject><subject>Ribonucleoproteins - immunology</subject><subject>Ribonucleoproteins - metabolism</subject><subject>SS-B Antigen</subject><subject>transglutaminase</subject><subject>Transglutaminases - metabolism</subject><subject>Tumor Cells, Cultured</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNpF0E1v0zAYwHELMbEx-AggX9gBKcMvcewcq3RApQ4kVM7WE-dJYpQmw0409dvjqEW72D78Htv6E_KBs3vOlfnCmTYZy6W4r6pfGdMZK4V4RW64UjqTolCv0_m_uSZvY_zDGM85y9-Qa66NVtrIG4KHHuke6GaZJxhn3-FId5ECfYTBdyOM7pRtYpychxkbWuEw0C3C3NMDhA5neuhhXid2Y7O4JOoT3f7YZFs4QufHjm7D0sV35KqFIeL7y35Lfn99OFTfs_3Pb7tqs89czuScVm6U1toxbKQEBUWNosxzI1qFmre11M61rsmdAmFM48pGaqYLVmBRq8LIW3J3vvcpTH8XjLM9-ujSn2HEaYmWl1qqPBcJqjN0YYoxYGufgj9COFnO7NrXru3s2s6mvpZpu_ZNcx8vDyz1EZuXqUvQBD5dAEQHQxtSQR9fXCk4LwqV3Oez633XP_uA1iWJIWBECK63XFpurFKsjPIfEZmQSQ</recordid><startdate>20070915</startdate><enddate>20070915</enddate><creator>Al-Ejeh, Fares</creator><creator>Darby, Jocelyn M</creator><creator>Brown, Michael P</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>H94</scope></search><sort><creationdate>20070915</creationdate><title>The La Autoantigen Is a Malignancy-Associated Cell Death Target That Is Induced by DNA-Damaging Drugs</title><author>Al-Ejeh, Fares ; Darby, Jocelyn M ; Brown, Michael P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-c4185777c0ed33a5a6be294482f5e71fb37ccfcd4c5a288dc9d3707606e6b5683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - toxicity</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis - physiology</topic><topic>Autoantigens - immunology</topic><topic>Autoantigens - metabolism</topic><topic>Biological and medical sciences</topic><topic>cell death</topic><topic>Chromatin - metabolism</topic><topic>Cisplatin - toxicity</topic><topic>Cross-Linking Reagents - pharmacology</topic><topic>DNA Breaks, Double-Stranded - drug effects</topic><topic>DNA damage</topic><topic>DNA, Neoplasm - drug effects</topic><topic>Flow Cytometry</topic><topic>Fluorescent Antibody Technique</topic><topic>GTP-Binding Proteins - metabolism</topic><topic>Histones - metabolism</topic><topic>Humans</topic><topic>Immunoblotting</topic><topic>La/SSB</topic><topic>Lymphocytes - drug effects</topic><topic>Medical sciences</topic><topic>Monocytes - drug effects</topic><topic>Necrosis</topic><topic>Neoplasms - genetics</topic><topic>Neoplasms - metabolism</topic><topic>Neoplasms - pathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Glutamine gamma Glutamyltransferase 2</topic><topic>ribonucleoprotein</topic><topic>Ribonucleoproteins - antagonists &amp; inhibitors</topic><topic>Ribonucleoproteins - immunology</topic><topic>Ribonucleoproteins - metabolism</topic><topic>SS-B Antigen</topic><topic>transglutaminase</topic><topic>Transglutaminases - metabolism</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Ejeh, Fares</creatorcontrib><creatorcontrib>Darby, Jocelyn M</creatorcontrib><creatorcontrib>Brown, Michael P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Ejeh, Fares</au><au>Darby, Jocelyn M</au><au>Brown, Michael P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The La Autoantigen Is a Malignancy-Associated Cell Death Target That Is Induced by DNA-Damaging Drugs</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2007-09-15</date><risdate>2007</risdate><volume>13</volume><issue>18</issue><spage>5509s</spage><epage>5518s</epage><pages>5509s-5518s</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Purpose: To evaluate the La autoantigen as a target for specific monoclonal antibody (mAb) binding in dead cancer cells after use of DNA-damaging chemotherapy. Experimental Design: In vitro studies of La-specific 3B9 mAb binding to malignant and normal primary cells with and without cytotoxic drug treatment were done using immunoblotting and flow cytometry. Chromatin-binding studies and immunofluorescence detection of γH2AX as a marker of DNA double-stranded breaks together with 3B9 binding assays were done to measure DNA damage responses. Incorporation of a transglutaminase 2 (TG2) substrate and TG2 inhibition were studied to measure protein cross-linking in dead cells. Results: La was overexpressed in human cancer cell lines with respect to normal primary cells. Within 3 h of the DNA-damaging stimulus, La became chromatin bound when it colocalized with γH2AX. Later, after the stimulus produced cell death, La-specific 3B9 mAb bound specifically and preferentially in the cytoplasm of dead cancer cells. Moreover, 3B9 binding to dead cancer cells increased with increasing DNA damage. Both La and 3B9 became cross-linked in dead cancer cells via TG2 activity. Conclusion: La autoantigen represents a promising cancer cell death target to determine chemotherapy response because its expression was selectively induced in dead cancer cells after DNA-damaging chemotherapy.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>17875783</pmid><doi>10.1158/1078-0432.CCR-07-0922</doi></addata></record>
fulltext fulltext
identifier ISSN: 1078-0432
ispartof Clinical cancer research, 2007-09, Vol.13 (18), p.5509s-5518s
issn 1078-0432
1557-3265
language eng
recordid cdi_proquest_miscellaneous_19735442
source Freely Accessible Science Journals - check A-Z of ejournals
subjects Antibodies, Monoclonal - pharmacology
Antineoplastic agents
Antineoplastic Agents - toxicity
Apoptosis - drug effects
Apoptosis - physiology
Autoantigens - immunology
Autoantigens - metabolism
Biological and medical sciences
cell death
Chromatin - metabolism
Cisplatin - toxicity
Cross-Linking Reagents - pharmacology
DNA Breaks, Double-Stranded - drug effects
DNA damage
DNA, Neoplasm - drug effects
Flow Cytometry
Fluorescent Antibody Technique
GTP-Binding Proteins - metabolism
Histones - metabolism
Humans
Immunoblotting
La/SSB
Lymphocytes - drug effects
Medical sciences
Monocytes - drug effects
Necrosis
Neoplasms - genetics
Neoplasms - metabolism
Neoplasms - pathology
Pharmacology. Drug treatments
Protein Glutamine gamma Glutamyltransferase 2
ribonucleoprotein
Ribonucleoproteins - antagonists & inhibitors
Ribonucleoproteins - immunology
Ribonucleoproteins - metabolism
SS-B Antigen
transglutaminase
Transglutaminases - metabolism
Tumor Cells, Cultured
title The La Autoantigen Is a Malignancy-Associated Cell Death Target That Is Induced by DNA-Damaging Drugs
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T04%3A39%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20La%20Autoantigen%20Is%20a%20Malignancy-Associated%20Cell%20Death%20Target%20That%20Is%20Induced%20by%20DNA-Damaging%20Drugs&rft.jtitle=Clinical%20cancer%20research&rft.au=Al-Ejeh,%20Fares&rft.date=2007-09-15&rft.volume=13&rft.issue=18&rft.spage=5509s&rft.epage=5518s&rft.pages=5509s-5518s&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-07-0922&rft_dat=%3Cproquest_cross%3E19735442%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c403t-c4185777c0ed33a5a6be294482f5e71fb37ccfcd4c5a288dc9d3707606e6b5683%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=19735442&rft_id=info:pmid/17875783&rfr_iscdi=true